Sinaptica Therapeutics
PrivateLast Round
Grant
Dec 11, 2025
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Sinaptica Therapeutics is a neurotechnology company developing a personalized, non-invasive neuromodulation therapy to treat Alzheimer's and other primary neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Hardware + Subscription, Hardware Sales, Usage-Based SaaS, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sinaptica Therapeutics Comparables
Compare Sinaptica Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cognito Therapeutics | 82% | |
| Bottneuro AG | 80% | |
| REGEnLIFE | 76% |
Sinaptica Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 11, 2025 | ||||
| Convertible Debt | Jul 31, 2025 | ||||
| Seed | Nov 28, 2023 |
Sinaptica Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HealthTech Capital | Convertible Debt, Seed |
| Keiretsu Forum | Convertible Debt |
| Bootstrap Venture Partners | Convertible Debt |
| 1004 Venture Partners | Convertible Debt, Series A |
| Pureland Venture | Convertible Debt |
| Baycrest Hospital | Grant |
| Wilson Sonsini Goodrich & Rosati | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
Monthly visitors increased 43% MoM, reaching 1.6K.
- Dec 11, 2025
Received grant funding from Baycrest Hospital and CABHI.
Sinaptica Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sinaptica Therapeutics's valuation, stock price, and market status.
Is Sinaptica Therapeutics a public or private company?
Sinaptica Therapeutics is a private company.
What is the current stock price of Sinaptica Therapeutics?
Sinaptica Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Sinaptica Therapeutics worth (valuation)?
Valuation information for Sinaptica Therapeutics is not publicly available.
Can I buy Sinaptica Therapeutics stock?
Sinaptica Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Sinaptica Therapeutics's last funding round?
Sinaptica Therapeutics's most recent funding round was Grant on December 11, 2025.
Who are the main investors in Sinaptica Therapeutics?
Key investors in Sinaptica Therapeutics include HealthTech Capital, Keiretsu Forum, Bootstrap Venture Partners, 1004 Venture Partners, Pureland Venture.
Will Sinaptica Therapeutics IPO soon?
No public IPO plans have been announced for Sinaptica Therapeutics.
How can I track Sinaptica Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sinaptica Therapeutics's secondary market activity and sign up for updates.